PALATIN TECHNOLOGIES INC
Business
Palatin Technologies is a biopharmaceutical company developing first-in-class therapeutics based on melanocortin receptor agonists and antagonists to treat obesity, inflammatory diseases, sexual dysfunction, and rare metabolic disorders. The company's product candidates include MC4R agonist peptides and small molecules for obesity and metabolic disorders, MC1R agonists for inflammatory and autoimmune indications including dry eye disease and inflammatory bowel disease, and bremelanotide combinations for obesity and erectile dysfunction. Palatin employs a development-and-partner strategy, retaining early-stage programs while licensing mature assets to industry collaborators for commercialization and distribution.
Summary from 10-K filed 2025-09-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Product revenue, net | 0 | 4 | 5 | 1 | −188,597 | |
| Cost of products sold | 0 | 97,637 | — | — | — | |
| Research and development | 15 | 22 | 23 | 21 | 13 | |
| Selling, general and administrative | 8 | 12 | 15 | 17 | — | |
| Loss (Gain) on sale of Vyleesi | −3 | −8 | — | — | — | |
| Gain on purchase commitment | −2 | 0 | −1 | 0 | — | |
| Total operating expenses | 17 | 27 | 37 | 38 | 33 | |
| Loss from operations | −17 | −22 | −32 | −37 | −33 | |
| Investment income | 167,665 | 376,843 | 691,981 | 29,963 | 23,572 | |
| Foreign currency transaction (loss) gain | −50 | 59,753 | −429,971 | 389,868 | −212,526 | |
| Interest expense | −15,025 | −17,114 | −20,013 | −29,682 | −23,440 | |
| Offering expenses | 0 | −696,912 | −1 | — | — | |
| Change in fair value of warrant liabilities | 0 | −7 | — | — | — | |
| Total other income (expense), net | 152,590 | −7 | 4 | 390,149 | — | |
| NET LOSS | −17 | −30 | −24 | −36 | −34 | |
| Basic and diluted net loss per common share | −32.15 | −101.16 | — | — | — | |
| Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share | 538,348 | 293,951 | — | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 10 | 8 | 30 | 60 | |
| Other receivables | 29,468 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 325,695 | 242,272 | 2 | 2 | 3 | |
| Total current assets | 3 | 10 | 16 | 35 | 66 | |
| Property and equipment, net | 129,444 | 388,361 | 684,910 | 539,314 | 94,817 | |
| Right-of-use assets - operating leases | 161,166 | 527,321 | 876,101 | 878,465 | 1 | |
| Other assets | 56,916 | 56,916 | 56,916 | 56,916 | 56,916 | |
| Total assets | 3 | 11 | 18 | 36 | 67 | |
| Accounts payable | 7 | 4 | 4 | 3 | 640,650 | |
| Accrued expenses | 881,412 | 4 | 7 | 7 | 6 | |
| Short-term operating lease liabilities | 129,812 | 380,542 | 354,052 | 371,124 | 351,853 | |
| Short-term finance lease liabilities | 0 | 46,014 | 106,392 | 100,921 | 0 | |
| Other current liabilities | 0 | 944,150 | 4 | 6 | 4 | |
| Total current liabilities | 8 | 10 | 15 | 16 | 11 | |
| Long-term operating lease liabilities | 33,969 | 163,782 | 544,323 | 529,398 | 900,520 | |
| Other long-term liabilities | 0 | 1 | 2 | — | — | |
| Total liabilities | 8 | 11 | 20 | 20 | 18 | |
| Common stock of $0.01 par value authorized 300,000,000 shares: issued and outstanding 929,597 shares as of June 30, 2025 and 358,532 shares as of June 30, 2024 | 9,296 | 3,585 | 116,567 | 92,709 | 92,020 | |
| Additional paid-in capital | 454 | 442 | 410 | 404 | 401 | |
| Accumulated deficit | −459 | −442 | −412 | −388 | −352 | |
| Total stockholders deficiency | −5 | −111,497 | −2 | 16 | 50 | |
| Total liabilities and stockholders deficiency | 3 | 11 | 18 | 36 | 67 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net loss | −17 | −30 | −28 | −36 | — | |
| Depreciation and amortization | 258,917 | 339,075 | 288,331 | 126,668 | — | |
| Decrease in right-of-use asset | 366,155 | 348,780 | 371,339 | — | — | |
| Unrealized foreign currency transaction loss (gain) | 50 | −59,753 | 429,971 | −389,868 | — | |
| Stock-based compensation | 1 | 2 | 2 | 3 | 3 | |
| Change in fair value of liability classified warrants | 0 | 7 | 5 | — | — | |
| Gain on sale of Vyleesi | −3 | −8 | 0 | — | — | |
| Accounts receivable | 0 | 3 | 1 | −199,577 | −2 | |
| Other receivables | −29,468 | 0 | — | — | — | |
| Prepaid expenses and other assets | −83,423 | 1 | 35,173 | 1 | −2 | |
| Inventories | 0 | −1 | −418,471 | 217,529 | −987,237 | |
| Accounts payable | 3 | −201,598 | 1 | 3 | −75,022 | |
| Accrued expenses | −3 | −2 | −364,157 | 1 | 558,281 | |
| Operating lease liabilities | −380,543 | −354,051 | −371,122 | −351,851 | −316,279 | |
| Other liabilities | 141,400 | −3 | −2 | — | — | |
| Net cash used in operating activities | −21 | −31 | −29 | −30 | −93,638 | |
| Maturity of marketable securities | 0 | 3 | 0 | — | — | |
| Proceeds from sale of Vyleesi | 3 | 10 | — | — | — | |
| Purchases of property and equipment | 0 | −42,526 | −433,927 | −261,374 | −5,722 | |
| Net cash provided by investing activities | 3 | 12 | −3 | −261,374 | −5,722 | |
| Payment of withholding taxes related to restricted stock units | −99,482 | −56,401 | −146,062 | −221,311 | −93,638 | |
| Proceeds from the sale of common stock and warrants, net | 8 | 15 | 11 | 0 | — | |
| Payment of finance lease obligations | −46,014 | −106,392 | −100,922 | −56,463 | 0 | |
| Proceeds from exercise of warrants | 3 | 6 | 78 | 280,000 | 0 | |
| Net cash provided by financing activities | 11 | 21 | 11 | 18,358 | −23 | |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | −7 | 2 | −22 | −30 | −23 | |
| Cash paid for interest | 15,025 | 17,114 | 20,013 | 29,682 | 23,440 | |
| Conversion of liability classified warrants | — | 11 | — | — | — | |
| Conversion of liability classified warrants upon warrant exercise | 0 | 2 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PALATIN TECHNOLOGIES INC's CIK number?
PALATIN TECHNOLOGIES INC's SEC CIK number is 0000911216 (911216). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PALATIN TECHNOLOGIES INC's SEC filings?
All of PALATIN TECHNOLOGIES INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PALATIN TECHNOLOGIES INC last report earnings?
PALATIN TECHNOLOGIES INC (PTN) most recently filed an earnings 8-K with the SEC on Nov 14, 2024, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001654954-24-014334). This is PALATIN TECHNOLOGIES INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is PALATIN TECHNOLOGIES INC's most recent earnings 8-K?
PALATIN TECHNOLOGIES INC's latest earnings 8-K (Item 2.02) was filed Nov 14, 2024 under accession 0001654954-24-014334. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PALATIN TECHNOLOGIES INC's latest earnings 8-K →
Look up any company's CIK number →